Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Model-Informed Precision Dosing of Vancomycin in Adults
2021-003670-31Phase 4Completed
- Sponsor
- Ghent University Hospital
- Start
- Aug 2021
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of vancomycin in Gram-positive bacterial infection (2 arms), sponsored by Ghent University Hospital. Primary endpoint: Proportion of patients reaching target AUC24h/MIC (400-600). Started Aug 2021; status: completed.
02
Drugs
vancomycin
03
Conditions
Gram-positive bacterial infection
Beyond the preview
Go deeper on 2021-003670-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003670-31.